INDIA LIVE DESKNIFTY 50:23,140.50(+0.34%)SENSEX:73,895.74(+0.43%)
RDU Global
🇮🇳
Home/Topics/Companies & Institutions/CG Oncology
Back to Newsroom
🏢Organization Dossier

CG Oncology

Curated news coverage, institutional background, regulatory filings, and investigative reporting across RDU Global.

6 Stories Indexed
Last Updated: Just Now
Verified Entity Intelligence
Global Health & Biotech 17 Nov 2026, 08:00 AM IST

Biotech Leads Bullish Market Talk as CG Oncology’s Bladder Cancer Data Fuels Breakout

Biotechnology has emerged as the most bullishly discussed corner of the market, with investor sentiment strengthening after a series of clinical readouts and regulatory milestones. The latest catalyst is CG Oncology’s bladder cancer program, which delivered a Phase 3 win that is now reshaping expectations for the company and adding momentum to the broader biotech trade.

By RDU Global Wire6 min read
Global Markets & Equities05 Nov 2026, 08:00 PM IST

Boehringer Returns to Sino Biopharma in $7.4 Billion Cancer Pact

Boehringer Ingelheim has struck a new oncology partnership with Sino Biopharma, reviving a relationship that now carries a headline value of up to $7.4 billion. The deal centers on preclinical bispecific T-cell engagers and antibody-drug conjugates, underscoring how large drugmakers are still willing to pay for early-stage cancer assets with long-dated optionality. The agreement adds another major cross-border licensing transaction to a market already defined by capital discipline, pipeline replenishment and intense competition for differentiated oncology platforms. For investors, the structure signals both the scale of demand for next-generation cancer modalities and the long development runway that will determine how much of the deal value ultimately becomes payable.

6 min readRead →
National Governance & Policy02 Nov 2026, 08:00 PM IST

Nadda Inaugurates Advanced Radiotherapy Facility at AIIMS Rajkot, Reaffirms Push for Better Cancer Care

Union Health Minister J.P. Nadda inaugurated an advanced radiotherapy facility at AIIMS Rajkot, underscoring the government’s commitment to expanding access to modern cancer treatment. The move is part of a broader effort to strengthen tertiary care infrastructure and reduce the burden on patients who often travel long distances for specialised oncology services.

5 min readRead →
Global Health & Biotech26 Oct 2026, 08:00 PM IST

Landmark Melanoma Vaccine Trial Cuts Recurrence or Death Risk by 42%, Raising Stakes for Cancer Biotech

A first-of-its-kind personalized cancer vaccine has reduced the risk of melanoma recurrence or death by 42% in a landmark trial, according to reports from the European Society for Medical Oncology meeting. The result strengthens the case for individualized immunotherapy and could reshape investor expectations for Moderna, Merck, and the broader oncology biotech sector.

4 min readRead →
Global Markets & Equities25 Oct 2026, 08:00 AM IST

Tango Reports 82% Tumor Response in Pancreatic Cancer Trial, Raising the Stakes in a Crowded Race

Tango Therapeutics said its combination therapy produced an 82% tumor response rate in an early-stage trial involving advanced pancreatic cancer, a result that could sharpen investor attention on one of oncology’s most difficult targets. The data add momentum to the company’s strategy, while also inviting scrutiny over durability, patient selection and whether the response can translate into a meaningful late-stage commercial opportunity.

5 min readRead →
Global Health & Biotech15 Oct 2026, 09:30 PM IST

Merck CEO Says Personalized Cancer Vaccine Could Be Made Faster as Pipeline Advances

Merck Chief Executive Robert Davis told CNBC he expects the company’s experimental personalized cancer vaccine to become faster to manufacture over time, signaling a potential shift from early-stage scientific promise toward more scalable production. The comments add fresh attention to a closely watched oncology program that investors view as a possible long-term growth driver for Merck and a broader test case for the commercial viability of personalized cancer immunotherapy.

5 min readRead →

🏢 About this Entity

Corporations, startups, regulatory bodies, central banks, ministries and judicial courts. All news mentioning this entity is automatically verified and aggregated into this live intelligence dossier.

Co-Occurring Entities

Entities frequently referenced alongside CG Oncology: